Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF)

P. Gavrilov, V. Zhuravlev, L. Archacova, S. Dolgikh (Saint-Petersburg, Russian Federation)

Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Session: Tuberculosis in immunocompromised hosts
Session type: Poster Discussion
Number: 1948
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Gavrilov, V. Zhuravlev, L. Archacova, S. Dolgikh (Saint-Petersburg, Russian Federation). Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF). Eur Respir J 2011; 38: Suppl. 55, 1948

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease
Year: 2003


Induced sputum (IS) angiogenic cytokines in patients with sarcoidosis (SA)
Source: Eur Respir J 2005; 26: Suppl. 49, 268s
Year: 2005

Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 655s
Year: 2004

Changes in the quantity of 1b-interleukin (IL-1b), tumor necrosis factor-a (TNF-a) and interferon-g (IF-g) in evaluation of the effectiveness of treatment of tuberculosis by DOTS
Source: Eur Respir J 2004; 24: Suppl. 48, 486s
Year: 2004

Liver function in patients with pulmonary tuberculosis (PT) before and during the initial phase of antituberculosis treatment (ATT)
Source: Eur Respir J 2002; 20: Suppl. 38, 365s
Year: 2002

Concentration of NO2-, a-acid protein (AAP), tumor necrotic factor (TNF-a), in the induced sputum of patients with bronchial asthma(BA) and chronic obstructive bronchitis (COB)
Source: Eur Respir J 2001; 18: Suppl. 33, 367s
Year: 2001

Aerosol delivery of an immunomodulator (interferon-γ 1b) within mouse lungs
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015


Polymorphism of multidrug resistance gene (MDR1), interleukin 4 (IL4), IL13 genes in asthmatic patients and patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Year: 2008

Matrix metalloproteinases (MMPs) and acute phase proteins (APP) in predicting the efficacy of intensive phase treatment (IPP) in patients with pulmonary tuberculosis (PT)
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


The effect of sputum processing on tumour necrosis factor (TNFα), secretory leukoprotease inhibitor (SLPI), interleukin-6 and leukotriene-B4 (LTB4) in chronic bronchitis and bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 364s
Year: 2001

Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007


QuantiFERON-TB GOLD vs. TST methods of detection tuberculosis infection in rheumatoid arthritis patients with previously TNF α inhibitors treatment
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011

Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008


Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014


Diagnostic value of tumour necrosis factor-α (TNF) in comparison to adenosine deaminase (ADA) in tuberculosis pleurisy
Source: Eur Respir J 2001; 18: Suppl. 33, 499s
Year: 2001

The use of phon resonant therapy (PRT) in treatment of patients with pulmonary tuberculosis, combined with infections, caused by chlamydia (C) and mycoplasma (M)
Source: Eur Respir J 2004; 24: Suppl. 48, 52s
Year: 2004

Relationship between interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), C-reaktive protein (CRP), albumin (ALB) and alkaline phosphatase (ALP) in bronchoalveolar lavage fluid (BALF) of patients with interstitial lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 98s
Year: 2006

Measurement of tumor necrosis factor (TNF)α, leukotriene B4 (LTB4), and interleukin 8 (IL8) in the exhaled breath condensate (EBC) in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 584s
Year: 2007

Re-activation of bovine tuberculosis in a patient treated with infliximab
Source: Eur Respir J 2008; 32: 229-231
Year: 2008



Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020